Sotatercept denied as not FDA-approved for this use by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for sotatercept are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare May Cite "Not FDA-Approved" for Sotatercept

This denial reason for sotatercept warrants careful reading. Sotatercept received FDA approval for pulmonary arterial hypertension (PAH) in 2024. If UHC has issued a "not FDA-approved" denial, there are typically two possible explanations: (1) the plan's system has not yet updated its coverage logic to reflect the approval, creating a purely administrative error; or (2) the prescription was written for a use that falls outside the specific FDA-approved indication — for example, a form of pulmonary hypertension other than PAH, or a combination scenario not described in the label.

In either case, this denial is challengeable.

## Verifying the Denial Basis

Request the full written denial from UHC citing the specific policy language and the clinical basis for the "not FDA-approved" determination. Compare it against the current FDA-approved label for sotatercept (available at DailyMed or FDA.gov) to confirm whether the prescribed use is, in fact, within the approved indication.

## Your Appeal Rights

• ERISA §503 / ACA §2719 internal appeal: If the denial reflects a plan error (approval predates the denial), the internal appeal process is the fastest path. Submit a copy of the FDA approval letter and the current prescribing information directly.
• External review: If internal appeal is denied, request independent external review by an IRO. External reviewers are not bound by the plan's internal coverage determinations. File within the window shown on your Explanation of Benefits — typically approximately four months.
• Expedited review: PAH is a serious and progressive condition. If the denial is causing treatment delay, request expedited review concurrently with the internal appeal.
• State insurance department: If the plan is a fully insured (non-ERISA) plan, your state insurance department has authority to intervene in wrongful denials of FDA-approved therapies.

## Documentation to Gather

1. FDA approval confirmation: Print the current FDA label and approval documents for sotatercept. Highlight the exact approved indication. 2. Diagnosis documentation: Right-heart catheterization confirming PAH diagnosis and classification, specialty notes confirming the patient falls within the approved indication. 3. Prescriber attestation: A letter from the prescribing specialist confirming the prescribed use matches the FDA-approved indication, citing the label. 4. UHC's denial reasoning: Obtain the clinical review notes UHC used to determine the denial — these are available to you under ERISA §503(g).

## Criteria-Mapping Structure

List the FDA-approved indication language verbatim. In the adjacent column, document exactly how the patient's diagnosis, as confirmed in the chart, matches that language. This one-for-one mapping is the core of your rebuttal — it demonstrates the denial rests on an error, not a clinical judgment.